Skip to content
Strategic Partnering
News
Contact Us
Menu
Strategic Partnering
News
Contact Us
Invest
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Menu
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Strategic Partnering
Contact Us
Menu
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Topical Creams
Systemic Administration
One-Time Delivery of APCs with KynA
About Us
Our Mission
Leadership
Grants
Strategic Partnering
Contact Us
Q&A with Mark S. Miller, Co-founder, Chairman and CEO of BirchBioMed Inc. Developing an Antifibrotic Therapeutic for the Prevention of Scaring and Breaking Down Existing Scars and an Autoimmune Platform for Reversing Type l Diabetes
https://www.ceocfointerviews.com/interviews/BirchBioMed18.htm